Effect of TLR agonists on gene regulation in the tumor microenvironment
| Mean fold-change in mRNA levels (vs PBS treated controls) | |||
|---|---|---|---|
| Gene | CpG ODN + 3M control | 3M-052 + CpG control | CpG ODN + 3M-052 |
| IL-12 | 2.23* ± 0.18 | 1.40 ± 0.19 | 3.39*** ± 0.11 |
| INFγ | 1.94* ± 0.15 | 1.87* ± 0.25 | 2.81** ± 0.24 |
| Granzyme B | 1.69* ± 0.07 | 1.87* ± 0.08 | 4.44*** ± 0.23 |
| Arg1 | 1.01 ± 0.09 | 0.63* ± 0.09 | 0.43** ± 0.08 |
| Nos2 | 1.83 ± 0.05 | 0.39** ± 0.04 | 0.09** ± 0.04 |
| CTLA-4 | 0.85* ± 0.03 | 0.52** ± 0.01 | 0.33*** ± 0.02 |
| TGFβ | 0.43* ± 0.03 | 0.45* ± 0.01 | 0.26** ± 0.02 |
Mice were treated as described in Figure 1. mRNA was isolated from tumor infiltrating cells one day after the second treatment and analyzed by RT-PCR. Each point represents the mean ± SD fold difference in cells from treated vs untreated tumor bearing mice derived from independently studying 6 mice/group in 2 independent experiments.
*, p < 0.05; **, p <0.01, ***, p <0.001 when compared to PBS treated controls. Note: the level of expression of all genes from mice treated with CpG ODN plus 3M-052 was also significantly different (p < .01 - 0.05) from that of mice treated with CpG ODN alone or 3M-052 alone.